In vivo monitoring of liposomal release in tumours following ultrasound stimulation.
Evjen, Tove J. a; Hagtvet, Eirik b; Moussatov, Alexei c; Rgnvaldsson, Sibylla a[phi]; Mestas, Jean-Louis c; Fowler, Andrew R. c; Lafon, Cyril c; Nilssen, Esben A. a,*
[Article] European Journal of Pharmaceutics & Biopharmaceutics. 84(3):526-531, August 2013.

(Format: HTML, PDF)

: Dioeleoylphosphatidylethanolamine (DOPE)-based liposomes were recently reported as a new class of liposomes for ultrasound (US)-mediated drug delivery. The liposomes showed both high stability and in vitro US-mediated drug release (sonosensitivity). In the current study, in vivo proof-of-principle of US triggered release in tumoured mice was demonstrated using optical imaging. Confocal non-thermal US was used to deliver cavitation to tumours in a well-controlled manner. To detect in vivo release, the near infrared fluorochrome Al (III) Phthalocyanine Chloride Tetrasulphonic acid (AlPcS4) was encapsulated into both DOPE-based liposomes and control liposomes based on hydrogenated soy phosphatidylcholine (HSPC). Encapsulation causes concentration dependent quenching of fluorescence that is recovered upon AlPcS4 release from the liposomes. Exposure of tumours to US resulted in a significant increase in fluorescence in mice administered with DOPE-based liposomes, but no change in the mice treated with HSPC-based liposomes. Thus, DOPE-based liposomes showed superior sonosensitivity compared to HSPC-based liposomes in vivo.

(C) 2013Elsevier, Inc.